Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Says User Fee Proposal Could Shorten Total Pre-market Review Times

This article was originally published in The Gray Sheet

Executive Summary

FDA's first crack at an industry user fee reauthorization proposal did not change review goals for 510(k)s, but did suggest some new processes to shorten overall review times for 510(k)s and PMAs alike.
Advertisement

Related Content

FDA Rejects Device Industry's Two-Year User Fee Plan
FDA Rejects Device Industry's Two-Year User Fee Plan
User Fee Negotiators Far Apart: Industry Seeks To Delay New Fee Levels Until FDA Improves Performance
User Fee Negotiators Far Apart: Industry Seeks To Delay New Fee Levels Until FDA Improves Performance
Interactive Review May Be Revamped In 2012 User Fee Agreement
Shuren On The Hill: Industry Should Take More Blame For Review Delays
Shuren On The Hill: Industry Should Take More Blame For Review Delays

Topics

Advertisement
UsernamePublicRestriction

Register

MT030115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel